Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Recruiting 29Active not recruiting 18Suspended 4Terminated 3Withdrawn 2Not yet recruiting 2Completed 2

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Breast 1

Conditions

Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1

Interventions

Specimen Handling 4Biopsy 4Magnetic Resonance Spectroscopy 3vactosertib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1pegamotecan 1neratinib 1ipatasertib 1fludarabine phosphate 1binimetinib 1aldesleukin 1X-Rays 1Trastuzumab 1Taxes 1Surveys and Questionnaires 1Phantoms, Imaging 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1NUC-1031 1N-acetylcochinol-O-phosphate 1Ipilimumab 1Interleukin-2 1IL32 protein, human 1Gemcitabine 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × Neoplasm Metastasis × Specimen Handling × Clear all
NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI)

Phase 1 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT05111561 2026-05-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡